Must Reads In AML
AML for July/August 2016
Predicting Risk of Post Auto-HCT Relapse in AML , Biol Blood Marrow Transplant; ePub 2016 Aug 18; Mule, et al
Treatment Patterns in Newly Diagnosed AML , Clin Lymphoma Myeloma Leuk; ePub 2016 Aug 10; Ma, et al
Therapy-Related AML Outcomes Evaluated , Clin Lymphoma Myeloma Leuk; ePub 2016 Aug 10; Sasaki, et al
Consider This to Assess Relapse Risk Before AlloHSCT, Biol Blood Marrow Transplant; ePub 2016 Jul 29; Luskin, et al
Autologous HCT in Intermediate-Risk AML Patients , Leuk Lymphoma; 2016 Jul; Mannis, Martin, et al
AML for May/June 2016
Genomic Classification and Prognosis in AML, N Engl J Med; 2016 Jun 9; Papaemmanuil, et al
Impact of Respiratory Status on Hyperleukocytic AML, Leuk Lymphoma; 2016 Jun; Van de Louw, et al
AML for January/February 2016
CMV Reactivation in Hematologic Disease, Does it confer protection?
Donor Leukocyte Infusion in Relapsed Leukemia and MDS, Comparing unrelated DLI with matched sibling DLI
Minimal Residual Disease in AML, Assessing its prognostic value
Hypomethylating Agents in Secondary AML, Evaluating prognoses after progression from myeolodysplastic syndromes
High Dose Daunorubicin in Acute Myeloid Leukemia, Studying possible benefits
AML for November/December 2015
Minimal Residual Disease in Acute Myeloid Leukemia, Should it be the basis for disease assessment?
Obesity in Acute Myelogenous Leukemia, Comparing survival rates in patients with APL and non-APL AML
Conditioning Following AlloHCT, Comparing myeloablative to reduced-intensity conditioning
Variant Allele Frequency in MDS, Do gene mutations have prognostic value?
Stem-Cell Transplantation in Older Patients, Studying survival in patients aged > 60 years
AML for September/October 2015
Risk of AML and MDS After First Cancers, Are type of cancer and radiation status informative?
MDS and AML in Breast Cancer, Studying associations with therapies
Lifestyle and Environmental Exposures in AML, Studying associations with risk
Umbilical Cord Blood Transfusions in AML, Are they effective in older patients?
Social Factors in AML , Do they increase mortality risk?